$Forte Biosciences(FBRX)$
这只股是唯一的产品失败并且放弃这个项目,未来是充满未知数的。唯一的出路是账上还有5千万美金。
iPhone转发:1回复:7喜欢:0

全部评论

ZacX09-07 22:47

嗯我这样说也说不清,不然你Google一下吧。
量化其实也是没神话了,70%的量化是亏损的

酸枣瓴09-07 22:38

请问有比较长期做量化的基金吗?国外的也可以,我想看看长期量化逻辑通不通。

ZacX09-07 22:30

嗯除非你做量化的

酸枣瓴09-07 22:14

基本凉凉,only asset,同时没有提前准备下一步。
还有套利的空间不?
看样子基本没了!

ZacX09-07 22:09

f FB-401 failed to the meet primary endpoint in atopic dermatitis. Consequently, Forte is discontinuing the development of FB-401. As FB-401 was the company's only asset, Nakae expects management to "quickly take the necessary steps to reduce cash burn." The analyst believes that options going forward include utilizing the remaining cash to acquire a new early stage asset to develop, or becoming a shell that another private company can reverse into.

hat FB-401 failed to meet statistical significance for primary endpoint in an atopic dermatitis trial and will be discontinued. Raja sees "little value left" and expects the stock to trade close to cash, the analyst tells investors

cash is under $3